The Vinod Balachandran Lab: Publications

The Vinod Balachandran Lab: Publications

Share
Share

2022

Schiller JT, Lowy DR, Frazer IH, Finn OJ, Vilar E, Lyerly HK, Gnjatic S, Zaidi N, Ott PA, Balachandran VP, Dietrich PY, Migliorini D. Cancer vaccines. Cancer Cell. 2022 June 13;40(6): doi:https://doi.org/10.1016/j.ccell.2022.05.015 https://www.cell.com/cancer-cell/fulltext/S1535-6108(22)00228-8

Zebboudj A, Amisaki M, Balachandran VP. ILC2s–Bipartisan politicians in cancer. Sci Immunol. 2022 Jun 3;7(72):eabq2791. doi: 10.1126/sciimmunol.abq2791. PMID: 35658014 https://www.science.org/doi/full/10.1126/sciimmunol.abq2791?af=R

Łuksza M, Sethna ZM, Rojas LA, Lihm J, Bravi B, Elhanati Y, Soares K, Amisaki M, Dobrin A, Hoyos D, Guasp P, Zebboudj A, Yu R, Chandra AK, Waters T, Odgerel Z, Leung J, Kappagantula R, Makohon-Moore A, Johns A, Gill A, Gigoux M, Wolchok J, Merghoub T, Sadelain M, Patterson E, Monasson R, Mora T, Walczak AM, Cocco S, Iacobuzio-Donahue C, Greenbaum BD, Balachandran VP. Neoantigen quality predicts immunoediting in survivors of pancreatic cancer. Nature. 2022 May 19. https://www.nature.com/articles/s41586-022-04735-9

Summaries: ACIRCancer DiscovCancer Cell

2021

Rojas LA, Balachandran VP. Scaling the immune incline in PDAC. Nat Rev Gastroenterol Hepatol. 2021 Jul;18(7):453-454. doi: 10.1038/s41575-021-00475-9. PMID: 34083798 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8173858/

2020

Moral JA, Leung J, Rojas LA, Ruan J, Zhao J, Sethna Z, Ramnarain A, Gasmi B, Gururajan M, Redmond D, Askan G, Bhanot U, Elyada E, Park Y, Tuveson DA, Goen M, Leach SD, Wolchok JD, DeMatteo RP, Merghoub T & Balachandran VP. ILC2s amplify PD-1 blockade by activating tissue-specific cancer immunity. Nature. 2020 Feb 19. https://doi.org/10.1038/s41586-020-2015-4

Summaries: Cancer CellCell Res

2019

Balachandran VP, Beatty GL, Dougan SK. Broadening the impact of immunotherapy to pancreatic cancer: challenges and opportunities. Gastroenterology. 2019 May;156(7):2056-2072. doi: 10.1053/j.gastro.2018.12.038. PMID: 30660727 https://www.sciencedirect.com/science/article/pii/S001650851930054X?via%3Dihub

2017

Balachandran VP, Łuksza M, Zhao JN, Makarov V, Moral JA, Remark R, Herbst B, Askan G, Bhanot U, Senbabaoglu Y, Wells DK, Cary CIO, Grbovic-Huezo O, Attiyeh M, Medina B, Zhang J, Loo J, Saglimbeni J, Abu-Akeel M, Zappasodi R, Riaz N, Smoragiewicz M, Kelley ZL, Basturk O; Australian Pancreatic Cancer Genome Initiative; Gönen M, Levine AJ, Allen PJ, Fearon DT, Merad M, Gnjatic S, Iacobuzio-Donahue CA, Wolchok JD, DeMatteo RP, Chan TA, Greenbaum BD, Merghoub T, Leach SD. Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer. Nature. 2017 Nov 8. doi: 10.1038/nature24462. [Epub ahead of print]. PMID: 29132146

Summaries: Nat Rev Clin OncolCancer Discov, NatureJama

Łuksza M, Riaz N, Makarov V, Balachandran VP, Hellmann MD, Solovyov A, Rizvi NA, Merghoub T, Levine AJ, Chan TA, Wolchok JD, Greenbaum BD. A neoantigen fitness model predicts tumour response to checkpoint blockade immunotherapy. Nature. 2017 Nov 8. doi: 10.1038/nature24473. [Epub ahead of print]. PMID: 29132144

2011

Balachandran VP, Cavnar MJ, Zeng S, Bamboat ZM, Ocuin LM, Obaid H, Sorenson EC, Popow R, Ariyan C, Rossi F, Besmer P, Guo T, Antonescu CR, Taguchi T, Yuan J, Wolchok JD, Allison JP, DeMatteo RP. Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido. Nature Medicine. 2011 Aug 28;17(9):1094-100. doi: 10.1038/nm.2438. PMID: 21873989